Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
Alexandra Pender,1 Robin L Jones1,2 1Sarcoma Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust, 2Division of Clinical Studies, The Institute of Cancer Research, London, UK Abstract: The outcome of patients with unresectable or metastatic soft tissue sarcoma (STS) remains poor with...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/61c57060328d44beabb0ff5b9876a106 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Alexandra Pender,1 Robin L Jones1,2 1Sarcoma Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust, 2Division of Clinical Studies, The Institute of Cancer Research, London, UK Abstract: The outcome of patients with unresectable or metastatic soft tissue sarcoma (STS) remains poor with few treatment options. A number of randomized trials in the first-line setting have shown no difference in overall survival between combination anthracycline schedules and single-agent doxorubicin. A Phase Ib/randomized Phase II trial of doxorubicin with or without the platelet-derived growth factor receptor-α (PDGFRα)-blocking antibody, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. The results of this trial led to the approval of olaratumab in combination with doxorubicin in adult anthracycline-naïve unresectable STS. In this review, we discuss the potential role of PDGFRα signaling, early clinical data with olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas. Keywords: olaratumab, sarcoma, PDGFR |
|---|